Contracts › FA864925P0362
FA864925P0362: Anti-Shock Injection to Improve Combat Casualty Care
Awarded to Nka Bio, Inc by Department of the Air Force.
$1.2Mobligated
$1.2Mpotential value
15 January 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | FA864925P0362 |
|---|---|
| Awardee | Nka Bio, Inc |
| Awarding agency | Department of the Air Force |
| Awarding office | FA8649 USAF SBIR STTR CNTRCTNG AFRL |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AC32 National Defense R&D Services; Defense-Related Activities; Applied Research |
| Place of performance | MD |
| Offers received | 115 |
| Period of performance | 15 July 2025 to 15 January 2027 |
| Potential end | 15 January 2027 |
| Estimated recompete solicitation | Now / imminent (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record